Centre Hospitalier Regional Universitaire

The medical center is at the forefront of research in Chronic Pulmonary Aspergillosis, focusing on innovative therapeutic approaches. The center's studies aim to enhance the clinical and radiological outcomes for patients through advanced treatment regimens.

• Itraconazole and Nebulised Ambisome® Therapy
• Comparative Efficacy Studies

By integrating novel drug combinations, the center is pioneering efforts to improve patient quality of life and treatment efficacy.

Specializing in Peripheral T-cell Lymphoma, the center is dedicated to advancing treatment protocols that significantly extend progression-free survival. The research focuses on the benefits of autologous stem cell transplantation in achieving complete response.

• Autologous Stem Cell Transplantation
• Progression-Free Survival Enhancement

Through cutting-edge clinical trials, the center is setting new standards in lymphoma care and patient outcomes.

The center is a leader in the study of Locally Advanced/Metastatic Urothelial Cancer, focusing on the efficacy of novel therapeutic agents. Research efforts are directed towards improving objective response rates and progression-free survival.

• Sacituzumab Govitecan Therapy
• RECIST 1.1 Criteria Evaluation

By exploring innovative drug combinations, the center aims to enhance treatment outcomes for patients with advanced urothelial cancer.

Focusing on the unique challenges of Double Diabetes, the center is investigating the impact of GLP1 agonist treatments on glycemic control. The research aims to optimize therapeutic strategies for patients with this complex condition.

• Semaglutide Efficacy
• Glycemic Target Achievement

Through targeted studies, the center is advancing the understanding and management of double diabetes.

The center is pioneering research in Metastatic Colorectal Cancer, focusing on the integration of regorafenib with multimodal chemotherapy. The goal is to improve progression-free survival in chemo-resistant cases.

• Regorafenib and Metronomic Chemotherapy
• Progression-Free Survival Studies

By exploring new treatment combinations, the center is enhancing therapeutic options for colorectal cancer patients.

Specializing in Advanced Gastric Cancer, the center is evaluating the efficacy of novel drug combinations to improve survival rates. The research focuses on HER2-overexpressing gastric adenocarcinoma.

• Evorpacept and Trastuzumab Therapy
• Overall Survival Improvement

Through innovative clinical trials, the center is advancing treatment protocols for gastric cancer.

The center is at the forefront of research in Idiopathic Pulmonary Fibrosis, focusing on the efficacy of glucocorticoids in reducing mortality. The studies aim to provide new insights into treatment strategies for acute exacerbations.

• Glucocorticoid Efficacy
• Mortality Reduction Studies

By exploring novel therapeutic approaches, the center is enhancing the management of pulmonary fibrosis.

Focusing on Relapsing Remitting Multiple Sclerosis, the center is investigating the neuroprotective effects of testosterone treatment. The research aims to improve remyelination and reduce thalamus atrophy.

• Testosterone Neuroprotection
• Remyelination Studies

Through advanced imaging techniques, the center is enhancing the understanding of multiple sclerosis treatment.

The center is leading research in Prostatic Adenocarcinoma, focusing on the effectiveness of adjuvant hormonal treatments post-prostatectomy. The studies aim to improve survival rates in high-risk patients.

• Adjuvant Hormonal Therapy
• Survival Rate Improvement

By optimizing treatment protocols, the center is advancing care for prostate cancer patients.

Specializing in Resectable Gastric Cancer, the center is evaluating the impact of perioperative treatments on pathologic response. The research focuses on enhancing surgical outcomes through innovative drug regimens.

• Spartalizumab and FLOT Therapy
• Pathologic Response Evaluation

Through comprehensive studies, the center is improving treatment strategies for gastric cancer patients.

The center is at the forefront of research in Squamous Cell Anal Carcinoma, focusing on the efficacy of novel chemoradiotherapy regimens. The studies aim to improve progression-free survival and clinical response rates.

• Spartalizumab and DCFm Therapy
• Progression-Free Survival Studies

By integrating advanced treatment protocols, the center is enhancing therapeutic outcomes for anal carcinoma patients.

Focusing on Multiple Myeloma, the center is investigating the efficacy of novel drug combinations in relapsed or refractory cases. The research aims to improve treatment responses and patient outcomes.

• Isatuximab and Pomalidomide Therapy
• Relapse Refractory Studies

Through innovative clinical trials, the center is advancing the management of multiple myeloma.

The center is leading research in Prostate Cancer, focusing on the antitumor activity of darolutamide in combination with radiotherapy. The studies aim to improve biological response rates in intermediate-risk patients.

• Darolutamide and Radiotherapy
• Biological Response Studies

By exploring novel treatment combinations, the center is enhancing therapeutic strategies for prostate cancer.

Specializing in Rectal Cancer, the center is evaluating the efficacy of neoadjuvant therapies in a watch-and-wait strategy. The research focuses on improving clinical complete response rates in advanced cases.

• Dostarlimab and Radiotherapy
• Watch-and-Wait Strategy

Through comprehensive studies, the center is advancing treatment protocols for rectal cancer patients.

The center is at the forefront of research in Colorectal and Gastroesophageal Cancer, focusing on the safety and efficacy of alternative chemotherapy options for patients with DPD deficiency.

• Trifluridine/Tipiracil Therapy
• DPD Deficiency Studies

By exploring novel treatment regimens, the center is enhancing therapeutic options for patients with specific genetic profiles.

Focusing on External Genital Warts, the center is investigating the efficacy of the HPV vaccine in preventing recurrence. The research aims to reduce relapse rates and improve patient outcomes.

• HPV Vaccine Efficacy
• Relapse Prevention Studies

Through targeted studies, the center is advancing the understanding and management of genital warts.